A study to determine efficacy and safety of zanubrutinib combined with pomalidomide in the treatment of primary or secondary central nervous system lymphoma
Latest Information Update: 28 Jul 2023
At a glance
- Drugs Pomalidomide (Primary) ; Zanubrutinib (Primary)
- Indications CNS cancer; Lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Jul 2023 New trial record
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association